NOVARTIS SCHIZOPHRENIA TREATMENT FANAPT(TM) (ILOPERIDONE) TABLETS NOW AVAILABLE FOR USE IN THE US

Schizophrenia is a Chronic, Severe and Disabling Mental Disorder
Affecting 2.4 million Americans

Novartis announced that Fanapt(TM) (iloperidone), the company’s
schizophrenia treatment, is now available for use across the US. Fanapt is a
twice-daily, oral antipsychotic, approved by the US Food and Drug
Administration (FDA) in May 2009 for the acute treatment of schizophrenia in
adults.

Schizophrenia is a chronic, severe and disabling mental disorder,
affecting 2.4 million Americans. Despite the availability of several agents
for treatment, as many as 74% of all patients discontinue their medication
before completing 18 months of treatment. People with schizophrenia have
varying levels of response and tolerance to available therapies. More than a
quarter of patients change their medications within a year, with a mean time
to switching of 100 days.

Fanapt is indicated for the acute treatment of schizophrenia in adults.
In clinical trials treatment with Fanapt resulted in significant improvement
in symptoms of schizophrenia as demonstrated on two major scales for
measuring the positive and negative symptoms of the disorder.

    SATELLITE FEEDS:
    Monday, January 11th, 2010         Monday, January 11th, 2010
    3:30 AM - 3:45 AM ET               1:15 PM - 1:30 PM ET
    Galaxy 19                          AMC 3
    C-Band                             C-Band
    Transponder 20                     Transponder 3
    Downlink Freq. 4100 Horizontal     Downlink Freq. 3760 Horizontal

NEWS: Fanapt Proven Effective for the Treatment of Schizophrenia in
Adults – Despite Available Medications, There Remains a Need for Additional
Treatment Options

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at:
http://multivu.prnewswire.com/broadcast/41920/press.html

    SOUNDBITES:
    * Dr. Peter Weiden/ Professor of Psychiatry Director, Psychotic Disorders
      Program, University of Illinois at Chicago
    * Department of Psychiatry, Center for Cognitive Medicine

    B-ROLL INCLUDES:
    * exterior shot of University of Illinois at Chicago (UIC) Medical Center
      signage
    * shot of UIC Department of Psychiatry signage
    * footage of Dr. Weiden working in office
    * footage of Dr. Weiden in laboratory with colleague

VIDEO PROVIDED BY: Novartis Pharmaceuticals Corporation

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,
1-800-653-5313 EXT. 3

SOURCE Novartis Pharmaceuticals Corporation